Overview

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients

Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Surgical excisions are one of the most frequent cutaneous wounds. This study will compare the safety and preliminary efficacy of a novel fixed-dose combination drug MRG-001 in pre-abdominoplasty surgical excisions and scar appearance in subjects undergoing elective abdominoplasty.
Phase:
Phase 2
Details
Lead Sponsor:
MedRegen LLC